Dr Kate Vandyke

Dr Kate Vandyke
 Position Research Fellow (C) (with PhD)
 Org Unit Medical Sciences
 Email kate.vandyke@adelaide.edu.au
 Telephone +61 8 8128 4390
 Location SAHMRI - South Australian Health and Medical Research Institute ,   West End Health Precinct

  • Biography/ Background

    • BMedSc (Hons) PhD

    Dr Vandyke is currently a Royal Adelaide Hospital Mary Overton Research Fellow in the Myeloma Research Laboratory, School of Medical Sciences, 成人大片, based at the South Australian Health and Medical Research Insititute (SAHMRI), Cancer Theme.

    Dr Vandyke's PhD research, completed in 2010, centred on characterising the off-target effects of tyrosine kinase inhibitors, like imatinib, on bone metabolism and skeletal growth in chronic myeloid leukaemia. Her current research interests involve elucidating the molecular and cellular mechanisms responsible for multiple myeloma disease progression, primarily focussing on investigating the mechanisms controlling myeloma dissemination.

    Dr Vandyke is an affiliate lecturer in the School of Medical Sciences and the School of Medicine, University of Adelaide. She is an elected member of the Haematology Society of Australia and New Zealand and has served on the committee of the Australian Society of Medical Research SA Division since 2014.

     

  • Publications

    1.      Cheong, C.M., Chow A.W.S., Fitter S., Hewett D.R., Martin S.K., Williams S.A., To L.B., Zannettino A.C.W., Vandyke K. Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research (2015), 332(1):24-38.

    2.      Gan Z.Y., Fitter S., Vandyke K., To L.B., Zannettino A.C.W., Martin S.K. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology (2015), 39(3):380-387-38.

    3.      Noll J.E., Hewett D.R., Williams S.A., Vandyke K., Kok C., To L.B., Zannettino A.C.W. SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia (2014), 16(7):572-585.

    4.      Noll J.E., Vandyke K., Zannettino A.C.W. The role of the “cancer stem cell niche” in cancer initiation and progression. Adult Stem Cell Niches. InTech (2014), Chapter 9, 291-320. ISBN: 978-953-51-1718-6.

    5.      Ahmed F., Dutta N.K., Zannettino A.C.W., Vandyke K., Choudhury N.R. Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applications. Biomacromolecules (2014), 15(4):1276-1287.

    6.      Vandyke K., Chow A.W., Williams S.A., To L.B., Zannettino A.C.W. Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. British Journal of Haematology (2013), 161(4):499-507.

    7.      Vandyke K., Zannettino A.C.W. Side-effects of tyrosine kinase inhibitors on growth in paediatric patients. In ‘Imatinib: Chemical Structure, Pharmacology and Adverse Effects’. Nova Science Publishers (2013), Chapter 7, 115-128. ISBN: 978-1-62808-304-0.

    8.      Arthur A., Panagopoulos R., Cooper L., Menicanin D., Parkinson I., Codrington J., Vandyke K., Zannettino A.C.W, Koblar S.A., Sims N.A., Matsuo K., Gronthos S. EphB4 enhances the process of endochondral ossification during bone fracture repair. Journal of Bone and Mineral Research (2012), 28(4):929-35.

    9.      Vandyke K., Fitter S., Drew J., Fukumoto S., Schultz C.G., Sims N.A, Yeung D.T., Hughes T.P., Zannettino A.C.W. Prospective histomorphometric and DXA evaluation of bone remodelling in imatinib-treated CML patients: evidence for site-specific skeletal effects. Journal of Clinical Endocrinology and Metabolism (2013), 98(1):67-76.

    10.  Fitter S., Vandyke K., Gronthos S., Zannettino A.C.W. Suppression of PDGF induced PI3K activity by imatinib promotes adipogenesis and adiponectin secretion. Journal of Molecular Endocrinology (2012), 48(3):229-40.

    11.  Vandyke K., Fitter S., Zannettino A.C.W. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer Journal (2011), 1(e2)doi:10.1038/bcj.2011.1.

    12.  Fitter S., Vandyke K., Schultz C.G., White D., Hughes T.P., Zannettino A.C.W. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? Journal of Clinical Endocrinology and Metabolism (2010), 95(8):3763-7.

    13.  Vandyke K., Dewar A.L., Diamond P., Fitter S., Schultz C.G., Sims N.A., Zannettino A.C.W. The tyrosine kinase inhibitor dasatinib dysregulates bone remodelling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research (2010), 25(8):1759-70.

    14.  Vandyke K., Dewar A.L., Fitter S., Hughes T.P., Zannettino A.C.W. Dysregulation of bone remodelling by imatinib mesylate. Blood (2010), 115(4):766-774.

    15.  Vandyke K., Dewar A.L., Farrugia A.N., Fitter S., Menicanin D., To L.B., Hughes T.P., Zannettino A.C.W. Imatinib mesylate causes growth plate closure in vivo. Leukemia (2009), 23(11):2155-2159.

    16.  Vandyke K., Dewar A.L., Farrugia A.N., Fitter S., To L.B., Hughes T.P., Zannettino A.C.W. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia (2009), 23(5):994-997.

    17.  Vandyke K., White M.Y., Nguyen-Khuong T., Ow K., Luk S.C.-W., Kingsley E.A., Rowe A., Pang S.F., Walsh B.J., Russell P.J. Plant-derived MINA-05 inhibits human prostate cancer proliferation in vitro and lymph node spread in vivo.      Neoplasia (2007), 9(4):322-331.

    18.  Vandyke K., Blair J.M., Jackson P. & Russell P.J. Androgen decreases osteoprotegerin expression in prostate cancer cells. Prostate Cancer Prostatic Dis (2007), 10(2):160-6.

     Google scholar:

The information in this directory is provided to support the academic, administrative and business activities of the 成人大片. To facilitate these activities, entries in the University Phone Directory are not limited to University employees. The use of information provided here for any other purpose, including the sending of unsolicited commercial material via email or any other electronic format, is strictly prohibited. The University reserves the right to recover all costs incurred in the event of breach of this policy.

Entry last updated: Thursday, 5 Sep 2024

To link to this page, please use the following URL:  /directory/kate.vandyke